Dataset Information


Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.

ABSTRACT: The addition of adjuvant chemotherapy to hormonal therapy is recommended for patients with estrogen receptor-positive (ER+), node-positive (N+) early breast cancer (EBC). Some of these patients, however, are not likely to benefit from treatment and may, therefore, be overtreated while also incurring unnecessary treatment-related adverse events and health care costs. The 21-gene Recurrence Score assay has been clinically validated and recommended for use in patients with ER+, node-negative (N0) EBC to assess the 10-year risk of distant disease recurrence and predict the likelihood of response to adjuvant chemotherapy. A growing body of evidence from several large phase III clinical trials reports similar findings in patients with ER+, N+ EBC. A systematic review of published literature from key clinical trials that have used the 21-gene breast cancer assay in patients with ER+, N+ EBC was performed. The Recurrence Score has been shown to be an independent predictor of disease-free survival, overall survival, and distant recurrence-free interval in patients with ER+, N+ EBC. Outcomes from decision impact and health economics studies further indicate that the Recurrence Score affects physician treatment recommendations equally in patients with N+ or N0 disease. It also indicates that a reduction in Recurrence Score-directed chemotherapy is cost-effective. There is a large body of evidence to support the use of the 21-gene assay Recurrence Score in patients with N+ EBC. Use of this assay could help guide treatment decisions for patients who are most likely to receive benefit from chemotherapy.


PROVIDER: S-EPMC4162320 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2021-01-01 | S-EPMC7921089 | BioStudies
2015-01-01 | S-EPMC4524752 | BioStudies
2020-01-01 | S-EPMC7048163 | BioStudies
1000-01-01 | S-EPMC4984867 | BioStudies
2018-01-01 | S-EPMC6058344 | BioStudies
2011-01-01 | S-EPMC3221521 | BioStudies
2015-01-01 | S-EPMC4679783 | BioStudies
2015-01-01 | S-EPMC4381203 | BioStudies
2017-01-01 | S-EPMC5695865 | BioStudies
2017-01-01 | S-EPMC5591181 | BioStudies